Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 57.33 2.05% 1.15
ZNTL closed up 2.05 percent on Wednesday, May 5, 2021, on 83 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical ZNTL trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Multiple of Ten Bearish Other 2.05%
Wide Bands Range Expansion 2.05%
Overbought Stochastic Strength 2.05%
Hammer Candlestick Bullish -4.59%
Doji - Bullish? Reversal -4.59%
Multiple of Ten Bullish Other -4.59%
Wide Bands Range Expansion -4.59%
Older End-of-Day Signals for ZNTL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 9 hours ago
Possible Inside Day about 10 hours ago
60 Minute Opening Range Breakout about 11 hours ago
Up 3% about 11 hours ago
Down 1% about 13 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Hormones Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Her2 Molecule Therapeutics Her2/Neu Transcription Factors Estrogen Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors

Is ZNTL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 62.79
52 Week Low 25.41
Average Volume 317,535
200-Day Moving Average 42.16
50-Day Moving Average 47.09
20-Day Moving Average 53.08
10-Day Moving Average 59.07
Average True Range 3.92
ADX 26.33
+DI 21.34
-DI 15.11
Chandelier Exit (Long, 3 ATRs ) 51.03
Chandelier Exit (Short, 3 ATRs ) 49.03
Upper Bollinger Band 67.44
Lower Bollinger Band 38.71
Percent B (%b) 0.65
BandWidth 54.12
MACD Line 3.97
MACD Signal Line 3.94
MACD Histogram 0.0313
Fundamentals Value
Market Cap 2.33 Billion
Num Shares 40.6 Million
EPS -99999.99
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.00
Price-to-Book 6.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 63.45
Resistance 3 (R3) 63.42 61.36 62.43
Resistance 2 (R2) 61.36 59.80 61.37 62.09
Resistance 1 (R1) 59.34 58.84 60.35 59.37 61.75
Pivot Point 57.28 57.28 57.78 57.29 57.28
Support 1 (S1) 55.26 55.72 56.27 55.29 52.91
Support 2 (S2) 53.20 54.76 53.21 52.57
Support 3 (S3) 51.18 53.20 52.23
Support 4 (S4) 51.21